A matched case-control study of a novel acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection

Gut and Liver

Volumn 4, Issue 1, 2010, Pages 25-30

  Kim, Yong Gil ^a   Jang, Byung Ik ^a   Kim, Tae Nyeun ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

Acid pump antagonists; Endoscopic submucosal dissection; Proton pump inhibitors; Rabeprazole; Revaprazan

Indexed keywords

PANTOPRAZOLE; RABEPRAZOLE; REVAPRAZAN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; ENDOSCOPIC SUBMUCOSAL DISSECTION; FEMALE; HUMAN; IATROGENIC DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH ULCER; ULCER HEALING;

EID: 77949856962     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2010.4.1.25     Document Type: Article

References (31)

1. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17:22-37.
2. Pope AJ, Boehm MK, Leach C, Ife RJ, Keeling D, Parsons ME. Properties of the reversible K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. I. In vitro activity. Biochem Pharmacol 1995;50:1543-1549.
3. Akimoto M, Hashimoto H, Shigemoto M, Maeda A, Yamashita K. Effects of antisecretory agents on angiogenesis during healing of gastric ulcers. J Gastroenterol 2005;40:685-689.
4. Okazaki M, Shimizu I, Ishikawa M, et al. Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine. J Med Invest 2007;54: 83-90.
5. Yeo M, Kwak MS, Kim DK, et al. The novel acid pump an tagonists for anti-secretory actions with their peculiar applications beyond acid suppression. J Clin Biochem Nutr 2006;38:1-8.
6. Ono H. Endoscopic submucosal dissection for early gastric cancer. Chin J Dig Dis 2005;6:119-121.
7. Sakita T, Fukutomi H. Endoscopic diagnosis. In: Yoshitoshi Y, ed. Ulcer of stomach and duodenum. Tokyo: Nankodo, 1971:198-208.
8. Howden CW, Jones DB, Peace KE, Burget DW, Hunt RH. The treatment of gastric ulcer with antisecretory drugs: relationship of pharmacological effect to healing rates. Dig Dis Sci 1988;33:619-624.
9. Oh TH, Jung HY, Choi KD, et al. Degree of healing and healing-associated factors of endoscopic submucosal dissection-induced ulcers after pantoprazole therapy for 4 weeks. Dig Dis Sci 2009;54:1494-1499.
10. Hashimoto T, Adachi K. Changes in gastric mucosal blood flow during healing of EMR-induced ulcer: comparison with peptic ulcer. Dig Endosc 1997;9:127-131.
11. Kakushima N, Yahagi N, Fujishiro M, et al. The healing process of gastric artificial ulcers after endoscopic submucosal dissection. Dig Endosc 2004;16:327-331.
12. Panes J, Casadevall M, Pique JM, Bosch J, Whittle BJ, Teres J. Effects of acute normovolemic anemia on gastric mucosal blood flow in rats: role of nitric oxide. Gastroenterology 1992;103:407-413.
13. Tarnawski A, Stachura J, Durbin T, Sarfeh IJ, Gergely H. Increased expression of epidermal growth factor receptor during gastric ulcer healing in rats. Gastroenterology 1992;102:695-698.
14. Lee SY, Kim JJ, Lee JH, et al. Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole. Gastrointest Endosc 2004;60:213-217.
15. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305.
16. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors: inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000;14 Suppl 1:74-81.
17. Suzuki M, Mori M, Miura S, et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med 1996;21:727-731.
18. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 1992;33:617-621.
19. McCabe RD, Young DB. Evidence of a K(+)-H(+)-ATPase in vascular smooth muscle cells. Am J Physiol 1992;262: H1955-H1958.
20. Suzuki H, Masaoka T, Minegishi Y, Motosugi Y, Miura S, Ishii H. Lansoprazole promotes gastric mucosal cell proliferation and migration by activating p44/p42 mitogen-activated protein kinase. Wound Repair Regen 2004;12:93-99.
21. Chang R, Chung IS, Park SH, et al. Phase III clinical trial of Revaprazan (Revanex(R)) for gastric ulcer. Korean J Gastrointest Endosc 2007;34:312-319.
22. Choi MG, Park SH, Kim SK, et al. Phase III clinical trial of Revaprazan (Revanex(R)) for gastritis. Korean J Gastrointest Endosc 2006;33:212-219.
23. Chung IS, Choi MG, Park SH, et al. Revaprazan (Revanex( R)), a novel acid pump antagonist, for duodenal ulcer: results of a double-blind, randomized, parallel, multi-center phase III clinical trial. Korean J Gastrointest Endosc 2005; 31:17-24.
24. Yu KS, Bae KS, Shon JH, et al. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers. J Clin Pharmacol 2004; 44:73-82.
25. Elso CM, Lu X, Culiat CT, et al. Heightened susceptibility to chronic gastritis, hyperplasia and metaplasia in Kcnq1 mutant mice. Hum Mol Genet 2004;13:2813-2821.
26. Roepke TK, Anantharam A, Kirchhoff P, et al. The KCNE2 potassium channel ancillary subunit is essential for gastric acid secretion. J Biol Chem 2006;281:23740-23747.
27. Franic TV, Judd LM, Robinson D, et al. Regulation of gastric epithelial cell development revealed in H(+)/K(+)-ATPase beta-subunit- and gastrin-deficient mice. Am J Physiol Gastrointest Liver Physiol 2001;281:G1502-G1511.
28. Masaoka T, Suzuki H, Hibi T. Gastric epithelial cell modality and proton pump inhibitor. J Clin Biochem Nutr 2008;42:191-196.
29. Driman DK, Wright C, Tougas G, Riddell RH. Omeprazole produces parietal cell hypertrophy and hyperplasia in humans. Dig Dis Sci 1996;41:2039-2047.
30. Bajaj JS, Zadvornova Y, Heuman DM, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009;104:1130-1134.
31. Ito K, Kinoshita K, Tomizawa A, et al. The effect of subchronic administration of 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2- methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d] pyridazine (CS-526), a novel acid pump antagonist, on gastric acid secretion and gastrin levels in rats. J Pharmacol Exp Ther 2008;326:163-170.